Key Takeaways
- Cigna has filed an antitrust lawsuit against Bristol Myers Squibb and its subsidiary Celgene, alleging that they unlawfully extended the monopoly on the cancer drug Pomalyst (pomalidomide) through illegal ‘pay-for-delay’ tactics.
Bristol Myers Squibb’s Celgene defrauded the US Patent Office, filed baseless lawsuits and used illicit reverse-payment settlements to “unlawfully extend,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?